Future prospective studies should validate these thresholds across diverse patient populations, including those with recent transfusions or haemoglobinopathies, and compare LHD% against reticulocyte biomarkers of iron‐dependent erythropoiesis, as reticulocyte Hb biomarkers (e.g., Ret‐He, CHr) are not available at our institution. This evidence concerns the gene GSTM1 and hemoglobinopathy.